Results 61 to 70 of about 5,337 (191)

Aducanumab: A fate undecided [PDF]

Chemical & Engineering News, 2020
Few drug development tales have had the twists and turns of aducanumab , Biogen’s antibody treatment for Alzheimer’s disease.
openaire   +1 more source

Navigating the Prescription Drug Information System

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 855-870, October 2026.
Information on new prescription drugs is increasingly complex and fragmented, posing challenges for healthcare professionals, patients, and payers. Clinicians require concise, actionable guidance to support prescribing decisions, while patients seek to balance benefits and harms when making decisions aligned with their treatment goals.
Irina V. Wang, Courtney Davis, Robin Forrest, Avi Cherla, Maximilian Siebert, Janice Cowden, Sophia Walker, Tamar Krishnamurti, Florence T. Bourgeois, Steven Woloshin, Anita K. Wagner, Huseyin Naci   +11 more
wiley   +1 more source

Can we learn lessons from the FDA's approval of aducanumab? [PDF]

, 2021
On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered reasonably likely to confer clinical benefit.
Liu, KY, Howard, R
core   +1 more source

Practical Considerations in the Administration of Aducanumab for the Neurologist

Neurology Clinical Practice, 2022
Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration (FDA) reserved for treatments that fill a significant unmet need.1 Its approval on June 7, 2021, has been met with an outpouring of opinions from prescribers, insurers ...
Coerver, Katherine, Yu, Melissa M., D'Abreu, Anelyssa, Wasserman, Marc, Nair, Kavita V.   +4 more
openaire   +2 more sources

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

A REVIEW ON ANTIBODY OF ADUCANUMAB-REDUCES THE PROGRESSION OF ALZHEIMER DISEASE.

, 2023
Alzheimer's disease is the most common form of dementia, affecting millions of people, including family members who often act as caregivers. This devastating disease is believed to account for 8% of total US healthcare spending, with medical and nursing ...
Kolage Sakshi, Shrutika Mote, Amol Supekar, Saurabh Saudar
core   +1 more source

Questions EMERGE as Biogen claims aducanumab turnaround [PDF]

, 2020
Trials of aducanumab in Alzheimer disease were previously discontinued following a phase III futility analysis, but Biogen now says that additional data indicate that longer exposure to the higher dose might be effective.
Liu, KY, Howard, R
core   +1 more source

An Integrative Strategy Delineates Modular Metabolic Remodeling and Potential Therapeutic Targets Across Metabolic Diseases

Advanced Science, Volume 13, Issue 52, 18 September 2026.
An integrative single‐cell atlas across multiple metabolic diseases reveals coordinated metabolic modules and disease‐shared versus disease‐specific pathway activities. By systematically comparing scoring strategies, a robust RankAve framework is established. Coupled with network analysis and drug‐target prediction, this resource uncovers cross‐disease
Kuan Yang, Congxue Hu, Hang Zhao, Xiao Peng, Yiming Yan, Jiasi Wang, Wenqi Jiang, Depeng Mu, Yan Cao, Xia Li, Yunpeng Zhang   +10 more
wiley   +1 more source

Accelerated Approval of Highly Expensive Disease-modifying Agents: Lessons Learned From the Aducanumab Approval

Journal of Pharmacoeconomics and Pharmaceutical Management, 2022
Alzheimer’s disease (AD) is a neurodegenerative disease and the most common cause of dementia affecting millions of people yearly. On June 7, 2021, the U.S FDA granted accelerated approval to highly expensive Aducanumab (Aduhelm), the first-ever disease-
Santenna Chenchula, Padmavathi R.
doaj  

Enhancing early Alzheimer's disease clinical trials through prognostic score covariate adjustment

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION A prognostic score (PS) summarizes a patient's expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate. METHODS We pooled patient data from observational studies and randomized trials for early Alzheimer's disease (AD) and trained PS candidates to predict ...
Bruno T. Scodari, Roland Brown, Xiaotong Jiang, Changyu Shen, Kyle Ferber, Shuang Wu, Feng Gao, Szofia Bullain, Brian Millen   +8 more
wiley   +1 more source